#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Juvenile psoriatic arthritis Cardiac sarcoidosis Mantle cell lymphoma recurrent Amyotrophic lateral sclerosis Toxic epidermal necrolysis Congenital hypotransferrinaemia Peritoneal neoplasm Anaplastic large cell lymphoma T- and null-cell types Langerhans cell sarcoma Pemphigus Cutaneous T-cell lymphoma Osteochondrodysplasia Mantle cell lymphoma stage III Indolent systemic mastocytosis Chronic kidney disease More trials…

    Learn about Rare Diseases

    Hairy cell leukaemia recurrent Mucopolysaccharidosis II – Trials in Disease Cerebral arteriovenous malformation haemorrhagic – Treatment Hyperoxaluria – Diagnostics Medulloblastoma recurrent Marginal zone lymphoma refractory – Treatment Bronchiolitis obliterans syndrome Myelodysplastic syndrome with excess blasts – Trials in Disease Usher’s syndrome – Trials in Disease Ewing’s sarcoma recurrent – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Brimonidine Tartrate Rucaparib Rbl015.2 WEF-001 Mirabegron Ima402 Perindopril Arginine Cimetidine Vericiguat Montelukast Imipenem Monohydrate Sodium Alginate Ocrelizumab Dimethyl Fumarate 204-NETU Selumetinib Cytisine DISODIUM PHOSPHATE Nnc0194-0499 Deupirfenidone More therapies…

    Learn about Your Condition

    White matter lesion Nephrotic syndrome Liver transplant rejection Endometrial cancer Spermatocele Cardiac arrest Lumbosacral radiculopathy Peyronie's disease Duchenne muscular dystrophy Craniosynostosis Amyotrophic lateral sclerosis Haemolytic uraemic syndrome Laryngeal cancer stage III Dizziness Menopause More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Amyotrophic lateral sclerosis

  • A study to assess how SAR443820 is absorbed, broken down and removed by the body in healthy adult men

    Not recruiting

    1 1 1
    Investigated Diseases:
    • Amyotrophic lateral sclerosis
    Investigated Drugs:
    • SAR443820
    The Netherlands

  • Study on the Effects of ION363 for Patients with Amyotrophic Lateral Sclerosis with Fused in Sarcoma Mutations

    Not recruiting

    4 1 1
    Investigated Diseases:
    • Amyotrophic lateral sclerosis
    Investigated Drugs:
    • ULEFNERSEN
    Belgium Germany Ireland Italy The Netherlands Poland +2

  • Study on the Safety and Effects of AMT-162 Gene Therapy for Adults with SOD1 ALS

    Not recruiting

    1 1 1
    Investigated Diseases:
    • Amyotrophic lateral sclerosis
    Investigated Drugs:
    • ADENO-ASSOCIATED VIRAL VECTOR SEROTYPE RH10 ENCODING MIRNA AGAINST SOD1 MRNA
    Sweden

  • Study on the Effects of VHB937 in Patients with Amyotrophic Lateral Sclerosis (ALS)

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Amyotrophic lateral sclerosis
    Investigated Drugs:
    • VHB937
    Belgium Denmark Finland France Germany Ireland +5

  • Study on the Effects of Triumeq (Abacavir Sulfate, Lamivudine, Dolutegravir Sodium) in Patients with Amyotrophic Lateral Sclerosis (ALS)

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Amyotrophic lateral sclerosis
    Investigated Drugs:
    • Abacavir Sulfate
    • Dolutegravir Sodium
    • Lamivudine
    Ireland The Netherlands Slovenia Spain Sweden

  • Study of Tofersen for Adults with Presymptomatic Amyotrophic Lateral Sclerosis (ALS) Due to SOD1 Gene Mutation

    Not recruiting

    3 1
    Investigated Drugs:
    • Tofersen
    France Germany Italy Poland Spain Sweden
Previous Page
1 2 3 4 5 6
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!